8-K: Tonix Pharmaceuticals Highlights TNX-102 SL Data at Global Conference, NDA Submission on Track

Tonix Pharmaceuticals presented data on its TNX-102 SL sublingual formulation for fibromyalgia at the 11th Global Conference on Pharmaceutics and Drug Delivery Systems, highlighting its proprietary technology and pharmacokinetic properties.

Summary

• Tonix Pharmaceuticals presented data on TNX-102 SL at the 11th Global Conference on Pharmaceutics and Drug Delivery Systems (PDDS 2024).
• The presentations focused on the proprietary formulation technology and pharmacokinetic properties of TNX-102 SL, a sublingual cyclobenzaprine HCl product candidate.
• TNX-102 SL utilizes a eutectic formulation of cyclobenzaprine HCl and mannitol, which provides a stable product that dissolves rapidly and delivers the drug efficiently.
• The company expects composition and methods patents to provide market exclusivity until at least 2034 in the U.S., E.U., Japan, China, and other jurisdictions.
• The U.S. FDA New Drug Application (NDA) submission for TNX-102 SL is on track for October 2024, with a PDUFA date for FDA decision expected in 2025.
• Clinical studies showed that TNX-102 SL has a rapid absorption rate and bypasses first-pass metabolism, leading to higher levels of cyclobenzaprine and lower levels of the metabolite norcyclobenzaprine.
• The Phase 3 RESILIENT study demonstrated statistically significant improvement in the primary endpoint of fibromyalgia pain and in all six key secondary endpoints, including sleep quality.
• In vitro tests showed that disintegration time and wetting time are sensitive measures for assessing the quality of TNX-102 SL tablets.

Sentiment

Score: 8

Explanation: The document presents positive clinical trial results, a clear path to regulatory approval, and strong patent protection, indicating a positive outlook for the company and its product. The sentiment is very positive, but not a perfect 10 due to the inherent risks in pharmaceutical development.

Positives

• TNX-102 SL has a proprietary eutectic formulation that enhances drug delivery.
• The company has secured patents that are expected to provide market exclusivity until at least 2034.
• The FDA NDA submission is on track for October 2024, indicating progress towards regulatory approval.
• The Phase 3 RESILIENT study demonstrated statistically significant improvements in pain and sleep quality for fibromyalgia patients.
• TNX-102 SL has a rapid absorption rate and bypasses first-pass metabolism, potentially leading to better efficacy and reduced side effects.
• The in vitro tests developed are sensitive to differences in particle size, excipient content and compression strength, which will help with quality control.

Negatives

• The document does not explicitly mention any negatives, but it does acknowledge the risks associated with pharmaceutical development and regulatory approval.
• The document notes that the in vitro dissolution test does not discriminate between tablets made with intentional modifications to particle size, excipient content or compression strength, which could be a challenge for quality control if not for the other tests.

Risks

• The company faces risks related to obtaining FDA clearances or approvals.
• There are risks related to the successful marketing of any of their products.
• The company faces risks related to the timing and progress of clinical development of their product candidates.
• The company has a need for additional financing.
• There are uncertainties of patent protection and litigation.
• There are uncertainties of government or third party payor reimbursement.
• The company has limited research and development efforts and dependence upon third parties.
• The company faces substantial competition.

Future Outlook

The company is focused on submitting an NDA to the FDA in October 2024 for TNX-102 SL and anticipates a PDUFA date for FDA decision in 2025. They are also developing TNX-102 SL for acute stress reaction and have a contract with the U.S. Department of Defense to develop TNX-4200.

Management Comments

• Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals, stated that patents based on TNX-102 SL's eutectic composition have issued in multiple jurisdictions.
• Dr. Lederman also noted that there remains a significant unmet need in fibromyalgia for an effective treatment.
• Dr. Lederman concluded that the in vitro disintegration time and wetting time tests have supported an efficient clinical development process.
• Bruce Daugherty, Ph.D., Executive Vice President, Research at Tonix Pharmaceuticals, outlined the clinical pharmacology of TNX-102 SL.
• Siobhan Fogarty, Executive Vice President, Product Development at Tonix Pharmaceuticals, presented the development of in vitro techniques used to assess characteristics of the TNX-102 SL tablet.

Industry Context

This announcement is significant as it highlights the potential of TNX-102 SL to address the unmet needs in fibromyalgia treatment, a condition with limited effective options. The focus on a novel sublingual delivery method and the positive Phase 3 results position Tonix as a potential competitor in the pain management market.

Comparison to Industry Standards

• The document mentions three FDA-approved drugs for fibromyalgia: Pregabalin (Lyrica), Duloxetine (Cymbalta), and Milnacipran (Savella).
• TNX-102 SL is being positioned as a potential first new treatment option for fibromyalgia patients in 15 years, suggesting a significant gap in innovation in this area.
• The document highlights that 85% of patients fail first-line therapy with existing drugs, indicating a need for new treatments like TNX-102 SL.
• The company is comparing the pharmacokinetic properties of TNX-102 SL to oral cyclobenzaprine and AMRIX, demonstrating a focus on improved drug delivery and reduced side effects.
• The Phase 3 RESILIENT study results are compared to placebo, showing a statistically significant improvement in pain reduction, which is a key benchmark for fibromyalgia treatments.

Stakeholder Impact

• Shareholders may benefit from the positive clinical trial results and the potential for regulatory approval of TNX-102 SL.
• Fibromyalgia patients may benefit from a new treatment option that has shown statistically significant improvements in pain and sleep quality.
• Employees may benefit from the company's progress and potential for growth.
• The company's partners, such as Redox and APR, may benefit from the success of TNX-102 SL.

Next Steps

• The company plans to submit a New Drug Application (NDA) to the FDA in October 2024 for TNX-102 SL.
• The company anticipates a Prescription Drug User Fee Act (PDUFA) date for FDA decision on approval in 2025.
• The company will continue to develop TNX-102 SL for acute stress reaction.
• The company will continue to develop TNX-4200 small molecule broad-spectrum antiviral agents.

Key Dates

Keywords

TNX-102 SL, Fibromyalgia, Sublingual, Cyclobenzaprine, Eutectic Formulation, Pharmacokinetics, NDA, FDA, RESILIENT Study, Drug Delivery, Pain Management, Sleep Quality